Clinical and Molecular Hepatology (Clin Mol Hepatol, CMH)

Review

October 19, 2021

Crosstalk between tumor-associated macrophages and neighboring cells in hepatocellular carcinoma

Pil Soo Sung

Clin Mol Hepatol. 2022;28(3):333-350.

The tumor microenvironment generally shows a substantial immunosuppressive activity in hepatocellular carcinoma (HCC), accounting for the suboptimal efficacy of immune-based treatments for this difficult-to-treat cancer. The crosstalk between tumor cells...

Review

November 26, 2021

The best predictive model for hepatocellular carcinoma in patients with chronic hepatitis B infection

Jung Hwan Yu, Soon Gu Cho, Young-Joo Jin, et al.

Clin Mol Hepatol. 2022;28(3):351-361.

Chronic hepatitis B (CHB) seriously threatens human health. About 820,000 deaths annually are due to related complications such as hepatitis B and hepatocellular carcinoma (HCC). Recently, the use of oral...

Review

December 27, 2021

Imaging diagnosis of hepatocellular carcinoma: Future directions with special emphasis on hepatobiliary magnetic resonance imaging and contrast-enhanced ultrasound

Junghoan Park, Jeong Min Lee, Tae-Hyung Kim, et al.

Clin Mol Hepatol. 2022;28(3):362-379.

Hepatocellular carcinoma (HCC) is a unique cancer entity that can be noninvasively diagnosed using imaging modalities without pathologic confirmation. In 2018, several major guidelines for HCC were updated to include...

Review

January 13, 2022

Statin and aspirin for chemoprevention of hepatocellular carcinoma: Time to use or wait further?

Myung Ji Goh, Dong Hyun Sinn

Clin Mol Hepatol. 2022;28(3):380-395.

Preclinical studies highlighted potential therapeutic applications of aspirin and statins as anticancer agents based on their pleiotropic effects. Epidemiologic studies suggested the role of aspirin and statins in the chemoprevention...

Review

January 14, 2022

Intrahepatic cholangiocarcinoma: Tumour heterogeneity and its clinical relevance

Mina Komuta

Clin Mol Hepatol. 2022;28(3):396-407.

Treatment of intrahepatic cholangiocarcinoma (iCCA) is currently at a significant turning point due to the identification of isocitrate dehydrogenase (IDH) mutations and fibroblast growth factor receptor (FGFR) fusions that can...

Review

February 17, 2022

RNA interference as a novel treatment strategy for chronic hepatitis B infection

Rex Wan-Hin Hui, Lung-Yi Mak, Wai-Kay Seto, et al.

Clin Mol Hepatol. 2022;28(3):408-424.

Chronic hepatitis B (CHB) is a major cause of liver-related morbidity and mortality. Functional cure of CHB, defined as sustainable hepatitis B surface antigen (HBsAg) seroclearance, is associated with improved...

Review

July 1, 2022

Therapeutic mechanisms and beneficial effects of non-antidiabetic drugs in chronic liver diseases

Han Ah Lee, Young Chang, Pil Soo Sung, et al.

Clin Mol Hepatol. 2022;28(3):425-472.

The global burden of chronic liver disease (CLD) is substantial. Due to the limited indication of and accessibility to antiviral therapy in viral hepatitis and lack of effective pharmacological treatment...

Original Article

March 2, 2022

Non-alcoholic fatty liver disease increases risk of carotid atherosclerosis and ischemic stroke: An updated meta-analysis with 135,602 individuals

Ansel Shao Pin Tang, Kai En Chan, Jingxuan Quek, et al.

Clin Mol Hepatol. 2022;28(3):483-496.

Background/Aims: Non-alcoholic fatty liver disease (NAFLD) is associated with the development of cardiovascular disease. While existing studies have examined cardiac remodeling in NAFLD, there has been less emphasis on the...

Original Article

April 28, 2022

Discovery of dipeptidyl peptidase-4 inhibitor specific biomarker in non-alcoholic fatty liver disease mouse models using modified basket trial

Ju Hee Oh, Dae Won Jun, Hye Young Kim, et al.

Clin Mol Hepatol. 2022;28(3):497-509.

Background/Aims: We aimed to define an optimal target population and drug-specific biomarkers that may predict dipeptidyl peptidase (DPP)-4 inhibitor responses in non-alcoholic fatty liver disease (NAFLD). Methods: An exploration study (study...

Original Article

March 17, 2022

Association of non-alcoholic fatty liver disease with incident dementia later in life among elder adults

Seogsong Jeong, Yun Hwan Oh, Seulggie Choi, et al.

Clin Mol Hepatol. 2022;28(3):510-521.

Background/Aims: Accumulating evidence suggests a link between non-alcoholic fatty liver disease (NAFLD) and brain health. However, population-based evidence on the association between NAFLD and dementia remains unclear. This study was...

Original Article

May 4, 2022

Gut-derived lipopolysaccharide promotes alcoholic hepatosteatosis and subsequent hepatocellular carcinoma by stimulating neutrophil extracellular traps through toll-like receptor 4

Yang Liu, Xin Zhang, Shuo Chen, et al.

Clin Mol Hepatol. 2022;28(3):522-539.

Background/Aims: Binge drinking leads to many disorders, including alcoholic hepatosteatosis, which is characterized by intrahepatic neutrophil infiltration and increases the risk of hepatocellular carcinoma (HCC). Molecular mechanisms may involve the...

Original Article

May 6, 2022

Reappraisal of sepsis-3 and CLIF-SOFA as predictors of mortality in patients with cirrhosis and infection presenting to the emergency department: A multicenter study

Ji Hyun Kim, Baek Gyu Jun, Minjong Lee, et al.

Clin Mol Hepatol. 2022;28(3):540-552.

Background/Aims: Sepsis-3 criteria and quick Sequential Organ Failure Assessment (qSOFA) have been advocated to be used in defining sepsis in the general population. We aimed to compare the Sepsis-3 criteria...

Original Article

May 11, 2022

Effect of moderate-to-severe hepatic steatosis on neutralising antibody response among BNT162b2 and CoronaVac recipients

Ka Shing Cheung, Lok Ka Lam, Rex Wan Hin Hui, et al.

Clin Mol Hepatol. 2022;28(3):553-564.

Background/Aims: Studies of hepatic steatosis (HS) effect on COVID-19 vaccine immunogenicity are lacking. We aimed to compare immunogenicity of BNT162b2 and CoronaVac among moderate/severe HS and control subjects. Methods: Two hundred...

Original Article

May 19, 2022

The effect of diabetes and prediabetes on the prevalence, complications and mortality in nonalcoholic fatty liver disease

Cheng Han Ng, Kai En Chan, Yip Han Chin, et al.

Clin Mol Hepatol. 2022;28(3):565-574.

Background/Aims: Nonalcoholic fatty liver disease (NAFLD) is closely associated with diabetes. The cumulative impact of both diseases synergistically increases risk of adverse events. However, present population analysis is predominantly conducted...

Current Issue: Volume 28(3); Jul 2022

This archive contains links to the full-text of all issues of Clin Mol Hepatol.

Current issue

Volume 28(3); July

All issues

Vol. 28
2022

v.28(1)
Jan 2022

v.28(2)
Apr 2022

v.28(3)
Jul 2022

Vol. 27
2021

v.27(1)
Jan 2021

v.27(2)
Apr 2021

v.27(3)
Jul 2021

v.27(4)
Oct 2021

Vol. 26
2020

v.26(1)
Jan 2020

v.26(2)
Apr 2020

v.26(3)
Jul 2020

v.26(4)
Oct 2020

Vol. 25
2019

v.25(1)
Mar 2019

v.25(2)
Jun 2019

v.25(3)
Sep 2019

v.25(4)
Dec 2019

Vol. 24
2018

v.24(1)
Mar 2018

v.24(2)
Jun 2018

v.24(3)
Sep 2018

v.24(4)
Dec 2018

Vol. 23
2017

v.23(1)
Mar 2017

v.23(2)
Jun 2017

v.23(3)
Sep 2017

v.23(4)
Dec 2017

Vol. 22
2016

v.22(1)
Mar 2016

v.22(2)
Jun 2016

v.22(3)
Sep 2016

v.22(4)
Dec 2016

Vol. 21
2015

v.21(1)
Mar 2015

v.21(2)
Jun 2015

v.21(3)
Sep 2015

v.21(4)
Dec 2015

Vol. 20
2014

v.20(1)
Mar 2014

v.20(2)
Jun 2014

v.20(3)
Sep 2014

v.20(4)
Dec 2014

Vol. 19
2013

v.19(1)
Mar 2013

v.19(2)
Jun 2013

v.19(3)
Sep 2013

v.19(4)
Dec 2013

The Korean Journal of Hepatology1995 (Vol.1 No.1) to 2012 (Vol.18 No.1)

Vol. 18
2012

v.18(1)
Mar 2012

v.18(2)
Jun 2012

v.18(3)
Sep 2012

v.18(4)
Dec 2012

Vol. 17
2011

v.17(1)
Mar 2011

v.17(2)
Jun 2011

v.17(3)
Sep 2011

v.17(4)
Dec 2011

Vol. 16
2010

v.16(1)
Mar 2010

v.16(2)
Jun 2010

v.16(3)
Sep 2010

v.16(4)
Dec 2010

Vol. 15
2009

v.15(1)
Mar 2009

v.15(2)
Jun 2009

v.15(3)
Sep 2009

v.15(4)
Dec 2009

v.15(60)
Dec 2009

Vol. 14
2008

v.14(1)
Mar 2008

v.14(2)
Jun 2008

v.14(3)
Sep 2008

v.14(4)
Dec 2008

Vol. 13
2007

v.13(1)
Mar 2007

v.13(2)
Jun 2007

v.13(3)
Sep 2007

v.13(4)
Dec 2007

Vol. 12
2006

v.12(1)
Mar 2006

v.12(2)
Jun 2006

v.12(3)
Sep 2006

v.12(4)
Dec 2006

Vol. 11
2005

v.11(1)
Mar 2005

v.11(2)
Jun 2005

v.11(3)
Sep 2005

v.11(4)
Dec 2005

Vol. 10
2004

v.10(1)
Mar 2004

v.10(2)
Jun 2004

v.10(3)
Sep 2004

v.10(4)
Dec 2004

Vol. 9
2003

v.9(1)
Mar 2003

v.9(2)
Jun 2003

v.9(3)
Sep 2003

v.9(4)
Dec 2003

Vol. 8
2002

v.8(1)
Mar 2002

v.8(2)
Jun 2002

v.8(3)
Sep 2002

v.8(4)
Dec 2002

Vol. 7
2001

v.7(1)
Mar 2001

v.7(2)
Jun 2001

v.7(3)
Sep 2001

v.7(4)
Dec 2001

Vol. 6
2000

v.6(1)
Mar 2000

v.6(2)
Jun 2000

v.6(3)
Sep 2000

v.6(4)
Dec 2000

Vol. 5
1999

v.5(1)
Mar 1999

v.5(2)
Jun 1999

v.5(3)
Sep 1999

v.5(4)
Dec 1999

Vol. 4
1998

v.4(1)
Mar 1998

v.4(2)
Jun 1998

v.4(3)
Sep 1998

v.4(4)
Dec 1998

Vol. 3
1997

v.3(1)
Mar 1997

v.3(2)
Jun 1997

v.3(3)
Sep 1997

v.3(4)
Dec 1997

Vol. 2
1996

v.2(1)
Jun 1996

v.2(2)
Dec 1996

Vol. 1
1995

v.1(1)
Jun 1995

Clinical and
Molecular
Hepatology

Print ISSN: 2287-2728
Online ISSN: 2287-285X

First decision

09 Days

Publication after acceptance

07 Days

*Last 12 months

Viewed By 11276	Crosstalk between tumor-associated macrophages and neighboring cells in hepatocellular carcinoma
Viewed By 4890	A cost-effectiveness study of universal screening for hepatitis C virus infection in South Korea: A societal perspective
Viewed By 3942	KASL clinical practice guidelines for management of chronic hepatitis B
Viewed By 2819	Association between serum tumor necrosis factor-α and sarcopenia in liver cirrhosis
Viewed By 2715	KASL clinical practice guidelines: Management of nonalcoholic fatty liver disease

Cited By 45	Trends in the prevalence of chronic liver disease in the Korean adult population, 1998–2017
Cited By 38	KASL clinical practice guidelines: Management of nonalcoholic fatty liver disease
Cited By 35	Application of transient elastography in nonalcoholic fatty liver disease
Cited By 33	KASL clinical practice guidelines for liver cirrhosis: Varices, hepatic encephalopathy, and related complications
Cited By 33	Comparison of clinical practice guidelines for the management of chronic hepatitis B: When to start, when to change, and when to stop